2 Publikationsliste

2.1 Publication Metrics (Web of Science 5/2019)

Sum of times cited:	8.935
Average citations per item:	17,38
h-index:	51

2.2 Originalarbeiten

1. **Siegmund B**, Eigler A, Moeller J, Greten TF, Hartmann G, Endres S. Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents. *Eur J Pharmacol* 1997, 321:231-9.
2. **Siegmund B**, Eigler A, Hartmann G, Hacker U, Endres S. Adrenaline enhances LPS induced IL-10 synthesis: evidence for protein kinase A-mediated pathway. *Int J Immunopharmacol* 1998, 20:57-69.
3. Eigler A, **Siegmund B**, Emmerich U, Baumann KH, Hartmann G, Endres S. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. *J Leukoc Biol* 1998, 63:101-7.
4. Hartmann G, Bidlingmaier C, **Siegmund B**, Albrich S, Schulze J, Tschoep K, Eigler A, Lehr HA, Endres S. The specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. *J Pharmacol Exp Ther* 2000, 292:22-30.
5. Schnurr M, Then F, Galambos P, Scholz C, **Siegmund B**, Endres S, Eigler A. Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells. *J Immunol* 2000, 165:4704-9.
6. **Siegmund B**, Rieder F, Albrich S, Wolf K, Firestein GS, Boyle D, Lehr HA, Loher F, Hartmann G, Endres S, Eigler A. The adenosine kinase inhibitor GP515 improves experimental colitis in mice. *J Pharmacol Exp Ther* 2001, 296:99-105.
7. Melnikov VY, Ecder T, Fantuzzi G, **Siegmund B**, Lucia MS, Dinarello CA, Schrier RW, Edelstein CL. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. *J Clin Invest* 2001, 107:1145-52.
8. **Siegmund B**, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G, Dinarello CA, Endres S, Eigler A. Neutralization of IL-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. *Am J Physiol Regul Integr Comp Physiol* 2001, 281:R1264-73.
9. **Siegmund B**, Welsch J, Loher F, Meinhardt G, Emmerich B, Endres S, Eigler A. Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis. *Leukemia* 2001, 15:1564-71.
10. **Siegmund B**, Lehr HA, Fantuzzi G, Dinarello CA. IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. *Proc Natl Acad Sci U S A* 2001, 98:13249-54.
11. **Siegmund B**, Lear-Kaul KC, Faggioni R, Fantuzzi G. Leptin deficiency, not obesity, protects mice from Con A-induced hepatitis. *Eur J Immunol* 2002, 32:552-60.
12. Wieland CW, **Siegmund B**, Senaldi G, Vasil ML, Dinarello CA, Fantuzzi G. Pulmonary inflammation by *Pseudomonas aeruginosa* lipopolysaccharide, phospholipase C, and exotoxin A: role of interferon regulatory factor-1. *Infect Immun* 2002, 70:1352-8.
13. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, **Siegmund B**, Dinarello CA, Mascagni P. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. *Proc Natl Acad Sci U S A* 2002, 99:2995-3000.
14. **Siegmund B**, Lehr HA, Fantuzzi G. Leptin: a pivotal role in intestinal inflammation. *Gastroenterology* 2002, 122:2011-2025.
15. Kaser A, Novick D, Rubinstein M, **Siegmund B**, Enrich B, Koch RO, Vogel W, Kim SH, Dinarello CA, Tilg H. Interferon-alpha induces IL-18 binding protein in chronic hepatitis C patients. *Clin Exp Immunol* 2002, 129:332-8.

16. Melnikov VY, Faubel S, **Siegmund B**, Lucia MS, Ljubanovic D, Edelstein CL. Neutrophil-independent mechanisms of caspase-1 and IL-18-mediated ischemic acute tubular necrosis in mice. *J Clin Invest* 2002, 110:1083-91.

17. Loher F, Schmall K, Freytag P, Landauer N, Hallwachs C, Bauer C, **Siegmund B**, Rieder F, Lehr HA, Dauer M, Kapp JK, Endres S, Eigler A. The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. *J Pharm Exp Ther* 2003, 305:549-56.

18. Fantuzzi G, Banda NK, Guthridge C, Vondracek A, Kim SH, **Siegmund B**, Azam T, Sennello JA, Dinarello CA, Arend WP. Generation and characterization of mice transgenic for human IL-18 binding protein isoform a. *J Leuk Biol* 2003, 74:889-96.

19. Loher F, Bauer C, Landauer N, Schmall K, **Siegmund B**, Lehr HA, Dauer M, Schoenharting M, Endres S, Eigler A. The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. *J Pharm Exp Ther* 2004, 308:583-90.

20. **Siegmund B**, Sennello JA, Jones-Carson J, Gamboni-Robertson F, Lehr HA, Batra A, Fedke I, Zeitz M, Fantuzzi G. Leptin receptor on T lymphocytes modulates chronic intestinal inflammation in mice**.** *Gut* 2004, 53:965-72.

21. Taube C, Nick JA, **Siegmund B**, Duez C, Takeda K, Rha YH, Park JW, Joetham A, Poch K, Dakhama A, Dinarello CA, Gelfand EW. Inhibition of early airway neutrophilia does not affect the development of airway hyperresponsiveness. *Am J Resp Cell Mol Biol* 2004, 30:837-43.

22. **Siegmund B**, Sennello JA, Lehr HA, Senaldi G, Dinarello CA, Fantuzzi G. Frontline: Interferon regulatory factor-1 as a protective gene in intestinal inflammation: role of TCR$\gamma\delta$ T cells and interleukin-18 binding protein. *Eur J Immunol* 2004, 34:2356-64.

23. **Siegmund B**, Sennello JA, Lehr HA, Batra A, Fedke I, Zeitz M, Fantuzzi G. Development of intestinal inflammation in double IL-10 and leptin-deficient mice. *J Leuk Biol* 2004, 76:782-86.

24. Ludwiczek O, Vannier E, Borggraefe I, Kaser A, **Siegmund B**, Dinarello CA, Tilg H. Imbalance between interleukin-1 agonist and antagonists: relationship to severity of inflammatory bowel disease. *Clin Exp Immunol* 2004, 138:323-9.

25. Jones-Carson J, Fantuzzi G, **Siegmund B**, Dinarello CA, Tracey KJ, Wang H, Fang FC, Vazquez-Torres A. Suppressor alphabeta T lymphocytes control innate resistance to endotoxic shock. *J Infect Dis* 2005, 192:1039-46.

26. Fantuzzi G, Sennello JA, Batra A, Fedke I, Lehr HA, Zeitz M, **Siegmund B**. Defining the role of T cell-derived leptin in the modulation of hepatic or intestinal inflammation in mice. *Clin Exp Immunol* 2005, 142:31-8.

27. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL, **Siegmund B**, Fantuzzi G, Dinarello CA, Mascagni P. The histone deacetylase inhibitor ITF 2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. *Mol Med* 2005, 11:1-15.

28. Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F, Mascagni P, Fantuzzi G, Dinarello CA, **Siegmund B.** Histone hyperacetylation is associated with amelioration of experimental colitis in mice. *J Immunol* 2006, 176:5015-22.

29. Batra A, Pietsch J, Fedke I, Glauben R, Okur B, Stroh T, Zeitz M, **Siegmund B.** Leptin-dependent toll-like receptor expression and responsiveness in preadipocytes and adipocytes. *Am J Pathol* 2007, 170:1931-41.

30. Heimesaat MM, Fischer A, **Siegmund B**, Kupz A, Niebergall J, Fuchs D, Jahn HK, Freudenberg M, Loddenkemper C, Batra A, Lehr HA, Liesenfeld O, Blaut M, Göbel UB, Schumann RR, Bereswill S. Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. *PLoS One* 2007, 2:e662.

31. Glauben R, Batra A, Stroh T, Erben U, Fedke I, Lehr HA, Leoni F, Mascagni P, Dinarello CA, Zeitz M, **Siegmund B.** Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. *Gut* 2008, 57:613-22.

32. Stroh T, Batra A, Glauben R, Fedke I, Erben U, Kroesen A, Heimesaat MM, Bereswill S, Giradin S, Zeitz M, **Siegmund B.** Nucleotide oligomerization domains 1 and 2: regulation of expression and function in preadipocytes. *J Immunol* 2008, 181:3620-7.

33. Ludwiczek O, Vannier E, Moschen A, Salazar-Montes A, Borggraefe I, Gabay C, Enrich B, Kaser A, **Siegmund B**, Dinarello CA, Tilg H. Impaired counter regulation of interleukin-1 by the soluble IL-1 receptor type II in patients with chronic liver disease. *Scand J Gastroenterol* 2008, 43:1360-5.

34. Sennello JA, Fayad R, Pini M, Gove ME, Ponemone V, Cabay RJ, **Siegmund B**, Dinarello CA, Fantuzzi G. Interleukin-18 together with interleukin-12 induces severe acute pancreatitis in obese but not in nonobese leptin-deficient mice. Proc Natl Acad Sci U S A 2008, 105:8085-90.

35. Nave H, Mueller G, **Siegmund B**, Jacobs R, Stroh T, Schueler U, Hopfe M, Behrendt P, Buchenauer T, Pabst R, Brabant G. Resistance of Janus kinase-2 dependent leptin signaling in natural killer (NK) cells: a novel mechanism of NK cell dysfunction in diet-induced obesity. *Endocrinology* 2008, 149:3370-8.

36. Batra A, Okur B, Glauben R, Erben U, Ihbe J, Stroh T, Fedke I, Chang HD, Zeitz M, **Siegmund B**. Leptin: A critical regulator of $CD4^+$ T-cell polarization in vitro and in vivo. *Endocrinology* 2010, 151:56-62.

37. Stroh T, Erben U, Kühl AA, Zeitz M, **Siegmund B**. Combined pulse electroporation – a novel strategy for highly efficient transfection of human and mouse cells. *PLoS One* 2010, 5:e9488.

38. Höhne WJ, Karge T, **Siegmund B**, Preiss J, Hoffmann JC, Zeitz M, Fölsch UR. AN internet portal for the development of clinical practice guidelines. *Appl Clin Inform* 2010, 1:430-41.

39. Günther U, Kusch D, Heller F, Bürgel N, Leonhardt S, Daum S, **Siegmund B**, Loddenkemper C, Grünbaum M, Buhr HJ, Schulzke JD, Zeitz M, Bojarski C. Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random vs. targeted biopsy protocols. *Int J Colorectal Dis* 2011, 26:667-72.

40. Gerling M, Glauben R, Habermann JK, Kühl AA, Loddenkemper C, Lehr HA, Zeitz M, **Siegmund B**. Characterization of chromosomal instability in murine colitis-associated colorectal cancer. *PLoS One* 2011, 6:e22114.

41. Winter S, Rehm A, Wichner K, Scheel T, Batra A, **Siegmund B**, Berek C, Lipp M, Höpken UE. Manifestation of spontaneous and early autoimmune gastritis in CCR7-deficient mice. *Am J Pathol* 2011, 179:754-65.

42. Heimesaat MM, Dunay IR, Fuchs D, Trautmann D, Fischer A, Kühl AA, Loddenkemper C, Batra A, **Siegmund B**, Krell HW, Bereswill S, Liesenfeld O. Selective gelatinase blockage ameliorates acute DSS colitis. *Eur J Microbiol Immunol (Bp)* 2011, 1:228-36.

43. Heimesaat MM, Dunay IR, Fuchs D, Trautmann D, Fischer A, Kühl AA, Loddenkemper C, **Siegmund B**, Batra A, Bereswill S, Liesenfeld O. The distinct roles of MMP-2 and MMP-9 in acute DSS colitis. *Eur J Microbiol Immunol (Bp)* 2011, 1:302-10.

44. German IBD Study Group. [Adherence to the H1N1 vaccination recommendation in patients with Crohn's disease or ulcerative colitis]. *Dtsch Med Wochenschr* 2011, 136:939-43.

45. Shalapour S, Deiser K, Kühl AA, Glauben R, Krug SM, Fischer A, Sercan O, Chappaz S, Bereswill S, Heimesaat MM, Loddenkemper C, Fromm M, Finke M, Hämmerling GJ, Arnold B, **Siegmund B**, Schüler T. Interleukin-7 links T lymphocyte and intestinal epithelial cell homeostasis. *PLoS One* 2012, 7:e31939.

46. Schumann M, Winter S, Wichner K, May C, Kühl AA, Batra A, **Siegmund B**, Zeitz M, Schulzke JD, Lipp M, Höpken UE. CCR7 deficiency causes diarrhea associated with altered ion transport in colonocytes in the absence of overt colitis. *Mucosal Immunol* 2012, 5:377-87.

47. Coordes A, Andreou A, Erben U, Stroh T, Blunert K, Slavova N, **Siegmund B**, Buhr HJ, Kroesen AJ. Recombinant human beta 2-defensin fusion proteins as a tool to investigate defensin structure and function in small human intestinal tissue samples. *Inflamm Res* 2012, 61:1411-20.

48. Batra A, Heimesaat MM, Bereswill S, Fischer A, Glauben R, Kunkel D, Scheffold A, Erben U, Kühl A, Loddenkemper C, Lehr HA, Schumann M, Schulzke JD, Zeitz M, **Siegmund B**. Mesenteric fat – control site for bacterial translocation in colitis. *Mucosal Immunol* 2012, 5:580-91.

49. Schuster M, Glauben R, Plaza-Sirvent C, Schreiber L, Annemann M, Floess S, Kühl AA, Clayton LK, Sparwasser T, Schulze-Osthoff K, Pfeffer K, Huehn J, **Siegmund B**, Schmitz I. De novo Foxp3 expression is regulated by the atypical NFκB inhibitor $I\kappa B_{NS}$. *Immunity* 2012, 37:998-1008.

50. Kredel LI, Batra A, Stroh T, Kühl AA, Zeitz M, Erben U, **Siegmund B.** Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn's disease. *Gut* 2013, 62:852-62.

51. Rieder F, **Siegmund B**, Bundschuh DS, Lehr HA, Endres S, Eigler A. The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice. *PLoS One* 2013, 8:e56867.

52. Fluhr G, Mayerle J, Weber E, Aghdassi A, Simon P, Gress T, Seufferlein T, Mössner J, Stallmach A, Rösch T, Müller M, **Siegmund B**, Büchner-Steudel P, Zuber-Jerger I, Kantowski M, Hoffmeister A, Rosendahl J, Linhart T, Maul J, Czakó L, Hegyi P, Kraft M, Engel G, Kohlmann T, Glitsch A, Pickartz T, Budde C, Nitsche C, Storck K, Lerch MM. Pre-Study protocol MagPEP: A multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis. *BMC Gastroenterol* 2013, 13:11.

53. Glauben R, Sonnenberg E, Wetzel M, Mascagni P, **Siegmund B**. Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo. *J Biol Chem* 2014, 289:6142-51.

54. Bücker R, Schulz E, Günzel D, Bojarski, C, Lee IF, John LJ, Wiegand S, Janssen T, Wieler LH, Dobrindt U, Beutin L, Ewers C, Fromm M, **Siegmund B**, Troeger H, Schulzke JD. alpha-haemolysin of Escherichia coli in IBD: a potentiator of inflammatory activity in the colon. *Gut* 2014, 63:1893-901.

55. Compton F, Bojarski C, **Siegmund B**, van der Giet M. Use of a nutrition support protocol to increase enteral nutrition delivery in critically ill patients. *Am J Crit Care* 2014, 23:396-403.

56. Erben U, Loddenkemper C, Doerfel K, Spieckermann S, Haller D, Heimesaat MM, Zeitz M, **Siegmund B**, Kühl AA. A guide to histomorphological evaluation of intestinal inflammation in mouse models. *Int J Clin Exp Pathol* 2014, 7:4557-76.

57. Erben U, Pawlowski NN, Doerfel K, Loddenkemper C, Hoffmann JC, **Siegmund B**, Kühl AA. Targeting human CD2 by the monoclonal antibody CB.219 reduces intestinal inflammation in a humanized transfer colitis model. *Clin Immunol* 2015, 157:16-25.

58. Annemann M, Wang Z, Plaza-Sirvent C, Glauben R, Schuster M, Ewald Sander F, Mamareli P, Kühl AA, **Siegmund B**, Lochner M, Schmitz I. IkappaBNS regulates murine Th17 differentiation during gut inflammation and infection. *J Immunol* 2015, 194:2888-98.

59. Briest F, Berg E, Grass I, Freitag H, Kaemmerer D, Lewens F, Christen F, Arsenic R, Altendorf-Hofmann A, Kunze A, Sänger J, Knösel T, **Siegmund B**, Hummel M, Grabowski P. FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors. *Oncotarget* 2015, 6:8185-99.

60. Lissner, D, Schumann M, Batra A, Kredel LI, Kühl AA, Erben U, May C, Schulzke JD, **Siegmund B**. Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD. *Inflamm Bowel Dis* 2015, 21:1297-305.

61. Poralla L, Stroh T, Erben U, Sittig M, Liebig S, **Siegmund B**, Glauben R. Histone deacetylase 5 regulates the inflammatory responses of macrophages. *J Cell Mol Med* 2015, 19:2162-71.

62. Erben U, Pawlowski NN, Heimesaat MM, Loddenkemper C, Doerfel K, Spieckermann S, **Siegmund B**, Kühl AA. Preventive anti-CD2 treatment does not impair parasite control in a murine toxoplasmosis model. *Eur J Mircobio Immunol (BP)* 2015, 5:306-15.

63. Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, Hüppe D, Maaser C, Klugmann T, Kruis W, **Siegmund B**, Helwig U, Weismüller J, Drabik A, Stallmach A; German IBD Study Group. Azathioprine-induced acute pancreatitis in patients with inflammatory bowel disease – a prospective study on incidence and severity. *J Crohns Colitis* 2016, 10:61-8.

64. Volz MS, Farmer A, **Siegmund B**. Reduction of chronic abdominal pain in patients with inflammatory bowel disease through transcranial direct current stimulation: a randomized controlled trial. *Pain* 2016, 157:429-37.

65. Barmeyer B, Erko I, Fromm A, Bojarski C, Loddenkemper C, Dames P, Kerick M, **Siegmund B**, Fromm M, Schweiger MR, Schulzke JD. ENaC dysregulation through activation of MEK1/2 contributes to impaired Na+ absorption in lymphocytic colitis. *Inflamm Bowel Dis* 2016, 22:539-47.

66. Rausch P, Basic M, Batra A, Bischoff SC, Blaut M, Clavel T, Gläsner J, Gopalakrishnan S, Grassl GA, Günther C, Haller D, Hirose M, Ibrahim S, Loh G, Mattner J, Nagel S, Pabst O, Schmidt F, **Siegmund B**, Strowig T, Volynets V, Wirtz S, Zeissig S, Zeissig Y, Bleich A, Baines JF. Analysis of factors contributing to variation in the C57BL/6J fecal microbiota across German animal facilities. *Int J Med Microbiol* 2016, S1438-4221(16)30019-4.

67. Zimmermann J, Hübschmann T, Schattenberg F, Schumann J, Durek P, Riedel R, Friedrich M, Glauben R, **Siegmund B**, Radbruch A, Müller S, Chang HD. High-resolution microbiota flow cytometry reveals dynamic colitis-associated changes in fecal bacterial composition. *Eur J Immunol* 2016, 46:1300-3.

68. Cordes F, Brückner M, Lenz P, Veltman K, Glauben R, **Siegmund B**, Hengst K, Schmidt MA, Cichon C, Bettenworth D. MicroRNA-320a strengthens intestinal barrier function and follows the course of experimental colitis. *Inflamm Bow Dis* 2016, 22:2341-55.

69. Preiss JC, Barmeyer C, Bürgek N, Daum S, Epple HJ, Günther U, Maul J, **Siegmund B**, Schumann M, Tröger H, Stroux A, Adler A, Veltzke-Schlieker W, Jürgensen C, Wentrup R, Wiedenmann B, Binkau J, Hartmann D, Nötzel E, Domagk D, Wacke W, Wahnschaffe U, Bojarski C. EndoClot polysaccharide hemostatic system in nonvariceal gastrointestinal bleeding: results of a prospective multicenter observational pilot study. *J Clin Gastroenterol* 2016, 50:e95-e100.

70. Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, **Siegmund B**, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prosective multicenter observational study. *Aliment Pharmacol Ther* 2016, 44:1199-1212.

71. Pannell M, Labuz D, Celik MÖ, Keye J, Batra A, **Siegmund B**, Machelska H. Adoptive transfer of M2 macrophages reduces neuropathic pain via opioid peptides. *J Neuroinflammation* 2016 13:262.

72. Xu X, Meng Q, Erben U, Wang P, Glauben R, Kühl AA, Wu H, Ma CW, Hu M, Wang Y, Sun W, Jia J, Wu X, Chen W, **Siegmund B**, Qin Z. Myeloid-derived suppressor cells promote B-cell production of IgA in a TNFR2-dependent manner. *Cell Mol Immunol* 2017, 14(7):597-606.

73. Seifarth C, Börner L, **Siegmund B**, Buhr HJ, Ritz JP, Gröne J. Impact of staged surgery on quality of life in refractory ulcerative colitis. *Surg Endosc* 2017, 31(2):643-49.

74. Strangfeld A, Richter A, **Siegmund B**, Herzer P, Rockwitz K, Demary W, Ringer M, Meißner Y, Zink A, Listing J. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biological or conventional synthetic DMARDs. *Ann Rheum Dis* 2017, 76(3):504-10.

75. Japp AS, Hoffmann K, Schlickeiser S, Glauben R, Nikoaou C, Maecker HT, Braun J, Matzmohr N, Sawitzki B, **Siegmund B**, Radbruch A, Volk HD, Frentsch M, Kunkel D, Thiel A. Wild immunology assessed by multidimensional mass cytometry. *Cytometry* 2017, 91(1):85-95.

76. Freitag H, Christen F, Lewens F, Grass I, Briest F, Iwaszkiewicz S, **Siegmund B**, Grabowski P. Inhibition of mTORs catalytic site by PKI-587 is a promising therapeutic option for gastroenteropancreatic neuroendocrine tumor disease. *Neuroendocrinology* 2017, 105(1):90-104.

77. Barmeyer C, Schumann M, Meyer T, Zielinksi C, Zuberbier T, **Siegmund B**, Schulzke JD, Daum S, Ullrich R. Long-term response to gluten-free diet as evidence for non-celiac wheat sensitivity in one third of patients with diarrhea-dominant and mixed-type irritable bowel syndrome. *Int J Colorectal Dis* 2017, 32:29-39.

78. Schindlbeck KA, Becker J, Berger F, Mehl A, Rewitzer C, Geffe S, Koch PM, Preiß JC, **Siegmund B**, Maul J, Marzinzik F. Impact of restless legs syndrome in patients with inflammatory bowel disease on sleep, fatigue, and quality of life. *Int J Colorectal Dis* 2017, 32:125-30.

79. Barmeyer C, Erko I, Awad K, Fromm A, Bojarski C, Meissner S, Loddenkemper C, Kerick N, **Siegmund B**, Fromm M, Schweiger MR, Schulzke JD. Epithelial barrier dysfunction in lymphoytic colitis through cytokine-dependent internalization of claudin-5 and -8. *J Gastroenterol* 2017, 52(10):1090-1100.

80. Epple HJ, Friebel J, Moos V, Troeger H, Krug SM, Allers K, Schinnerling K, Fromm A, **Siegmund B**, Fromm M, Schulzke JD, Schneider T. Architectural and functional alterations of the small intestinal mucosa in classical Whipple's disease. *Mucosal Immunol* 2017, 10(6):1542-1552.

81. Nikolaus S, Schreiber S, **Siegmund B**, Bokemeyer B, Bästlein E, Bachmann O, Görlich D, Hofmann U, Schwab M, Kruis W. Patient education in a 14-month randomized trial fails to improve adherence in ulcerative colitis: Influence of demographic and clinical parameters on non-adherence. *J Crohns Colitis* 2017, 11(9):1052-1062.

82. Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, Hüppe D, Maaser C, **Siegmund B**, Schmidt C, Stallmach A, German IBD Study group. Azathioprine allows glucorticoid withdrawal - post hoc results of a prospective study in patients with inflammatory bowel diseases. *Z Gastroenterol* 2017 55(5):461-65

83. Ritter J, Zimmermann K, Jöhrens K, Mende S, Seegbarth A, **Siegmund B**, Hennig S, Todorova K, Rosenwald A, Daum S, Hummel M, Schumann M. T-cell repertoire in refractory coeliac disease. *Gut* 2018, 67(4):644-653.

84. Rieger K, Günther U, Erben U, Kühl A, Loddenkemper C, Pezzutto A, **Siegmund B**, Bojarski C. Confocal endomicrosopy in diagnosis of intestinal chronic graft-versus-host disease. *Hematol Oncol* 2018, 36(1):291-298.

85. Bernhardt A, Fehr A, Brandt S, Jerchel S, Ballhause TM, Philipsen L, Stolze S, Geffers R, Weng H, Fischer KD, Isermann B, Brunner-Weinzierl MC, Batra A, **Siegmund B**, Zhu C, Lindquist JA, Merstens PR. Inflammatory cell infiltration and resolution of kidney inflammation is orchestrated by the cold-shock protein Y-box binding protein. *Kidney Int* 2017, 92(5):1157-1177.

86. Nötling S, Rentsch J, Freitag H, Detjen K, Briest F, Möbs M, Weissmann V, **Siegmund B**, Auernhammer CJ, Aristizabal Prada ET, Lauseker M, Grossman A, Exner S, Fischer C, Grötzinger C, Schrader J, Grabowski P; German NET-Z study group. *PLoS One* 2017, 12(8):e0182852.

87. Muche M, Meyer U, **Siegmund B**, Somasundaram R, Epple HJ. Sustained off-treatment response after discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg-seronegative hepatitis B: a case series. *Top Antivir Med* 2017, 25(3):114-117

88. Kopylov U, Papamichael K, Katsanos K, Waterman M, Bar-Gil Shitrit A, Boysen T, Portela F, Peixoto A, Szilagyi A, Silva M, Maconi G, Christodoulou DK, Eliakim R, Rahier JF, Magro F, Drobne D, Ferrante M, Sonnenberg E, **Siegmund B**, Muls V, Thurm T, Yanai H, Dotan I, Raine T, Levin A, Israeli E, Ghalim F, Carbonnel F, Vemeire S, Ben-Horin S, Roblin X. Impact of infliximab and cyclosporine on the risk of colectomy in hospitalized patients with ulcerative colitis complicated by cytomegalovirus-A multicenter retrospective study. *Inflamm Bowel Dis* 2017, 23(9):1605-1613.

89. Wu H, Willimsky G, Qin Z, **Siegmund B***, Glauben R*. Oleate but not stearate induces the regulatory phenotype of myeloid-derived suppressor cells. *Scientific Rep* 2017, 7(1):7498. *both authors contributed equally

90. Taromi S, Lewens F, Arsenic R, Sedding D, Sänger J, Kunze A, Möbs M, Benecke J, Freitag H, Christen F, Kaemmerer D, Lupp A, Heilmann M, Lammert H, Schneider CP, Richter K, Hummel M, **Siegmund B**, Burger M, Briest F, Grabowski P. Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer. *Oncotarget* 2017, 8(57):97061-97078.

91. Briest F, Grass I, Sedding D, Möbs M, Christen F, Benecke J, Fuchs K, Kaemmerer D, Mende S, Sänger J, Kunze A, Geisler C, Freitag H, Lewens F, Worpenberg L, Iwaszkiewicz S, **Siegmund B**, Walther W, Hummel M, Graboski P. Mechanisms of targeting the MDM2-p53-FOXM1 axis in well-differentiated intestinal neuroendocrine tumors. *Neuroendocrinology* 2018, 107(1):1-23.

92. Bücker R, Krug SM, Moos V, Bojarski C, Schweiger MR, Kerick M, Fromm A, Janßen S, Fromm M, Hering NA; **Siegmund B**, Schneider T, Barmeyer C, Schulzke JD. Campylobacter jejuni impairs sodium transport and epithelial barrier function via cytokine release in human colon. *Mucosal Immunol* 2018, 11(2):575-577.

93. Turowski F, Hügle U, Dormann A, Bechtler M, Jakobs R, Gottschalk U, Nötzel E, Hartmann D, Lorenz A, Kolligs F, Veltzke-Schlieker W, Adler A, Becker O, Wiedenmann B, Bürgel N, Tröger H, Schumann M, Daum S, **Siegmund B**, Bojarski C. Diagnostic and therapeutic single-operator cholangiopancreatoscopy with SpyGlass DS^{TM}: results of a multicenter retrospective study. *Surg Endosc* 2018 32(9):3981-3988.

94. Lütt A, Michael K, Krüger D, Volz MS, Nassir M, Schulz E, Poralla L, Tangermann P, Bojarski C, Höltje M, Teegen B, Stöcker W, Schemann M, **Siegmund B**, Prüss H. High prevalence and functional effects of serum antineuronal antibodies in patients with gastrointestinal disorders.

Neurogastroenterol Motil 2018, 30(6):e13292.

95. Troeger H, Hering NA, Bojarski C, Fromm A, Barmeyer C, Uharek L, **Siegmund B**, Fromm M, Rieger K, Schulzke JD. Epithelial barrier dysfunction as permissive pathomechanisms in human intestinal graft-versus-host disease. *Bone Marrow Transplant* 2018, 53(8):1083-1086.
96. Burisch J, Gisbert JP, **Siegmund B**, Bettenworth D, Bohn Thomsen S, Cleynen I, Ding NJS, Furfaro F, Galanpoulos M, Grunert PC, Hanzel J, Knezevic Ivanoski T, Noor N, O'Morain N, Rodríguez-Lago I, Scharl M, Tua J, Uzzan M, Yassin NA, Baert F, Langholz E. Validation of the "United Registries for Clinical Assessment and Research" (UR-CARE), a European online registry for clinical care and research in Inflammatory Bowel Disease. *J Crohns Colitis* 2018, 12(5):532-537.
97. Becker J, Becker F, Schindlbeck KA, Poddubnyy D, Koch PM, Preiß JC, **Siegmund B**, Marzinik F, Maul J. Restless legs syndrome is a relevant comorbidity in patients with inflammatory bowel disease. *Int J Colorectal Dis* 2018, 33(7):955-62.
98. Kruis W, Neshta V, Pesegova M, Alekseeva O, Andreev P, Datsenko O, Levchenko O, Abdulkhakov S, Lozynskyy Y, Mostovoy Y, Soloviev K, Dorofeyev AE, Vieth M, Stiess M, Greinwald R, Morhbacher R, **Siegmund B**. Novel budesonide suppositories are effective and safe for treatment of acute ulcerative proctitis: a randomized clinical trial. *Clin Gastro Hepatol* 2018 Apr 24. pii: S1542-3565(18)30386-0. doi: 10.1016/j.cgh.2018.04.027.
99. Reiter R, Wetzel M, Hamesch KH, Strnad P, Asbach P, Haas M, **Siegmund B**, Trautwein C, Hamm B, Klatt D, Braun J, Sack I, Tzschaetzsch H. Comparison of non-invasive assessment of liver fibrosis in patients with alpha1-antitrypsin deficiency using magnetic resonance elastography (MRE), acoustic radiation force impulse (ARFI) quantification, and 2D-shear wave elastography (2D-SWE). *PLoS One* 2018*,* 13(4):e0196486.
100. Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biourlet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, **Siegmund B**, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M. Effectiveness and Saftey of Vedolizumab in Anti-TNF-Naive Patients with Inflammatory Bowel Disease-A Multicenter Retrospective European Study. *Inflamm Bowel Dis* 2018, 2018 May 18. doi: 10.1093/ibd/izy155. [Epub ahead of print]
101. Tangermann P, Branchi F, Itzlinger A, Daum S, Aschenbeck J, Schunert S, Maul J, Liceni T, Schröder A, Heller F, Möhler U, Spitz W, Graefe U, Radke M, Trenkel S, Schmitt M, Loddenkemper C, **Siegmund B**, Bojarski C, Schumann M. Low sensitivity of Simtomax of care test in detection of celiac disease in a prospective multicenter study. *Clin Gastro Hepatol,* 2018 Sep 26. pii: S1542-3565(18)31023-1.
102. Briest F, Wand Y, Arsenic R, Elezkurtaj S, Berg E, Greshake S, Lock AC, Hörsch D, Arnold CN, Hummel M, **Siegmund B**, Grabowski P. Immunohistochemical study of mitosis-regulatory proteins in gastroenteropancreatic neuroendocrine neoplasms. *Anticancer Res*, 2018, 38(7):3863-3870.
103. Zwinger LL, **Siegmund B**, Stroux A, Adler A, Veltzke-Schlieker W, Wentrup R, Jürgensen C, Wiedenmann B, Wiedbrauck F, Hollerbach S, Liceni T, Bojarski C. CapsoCam SV-1 versus PillCam SB 3 in the detection of obscure gastrointestinal bleeding: results of a prospective randomized comparative multicenter study. *J Clin Gastroenterol* 2019, 53(3):e101-e106.
104. Kredel LI, Jödicke LJ, Scheffold A, Gröne J, Glauben R, Erben U, Kühl AA, **Siegmund B**. T-cell composition in ileal and colonic creeping fat - separating ileal from colonic Crohn's disease. *J Crohns Colitis,* 2019, 13(1):79-91.
105. Kredel LI, Mundt P, van Riesen L, Jöhrend K, Hoffmann J, Loddenkemper C, **Siegmund B**, Preiß JC. Accuracy of diagnostic tests and new algorithm for diagnosing cytomegalovirus colitis in inflammatory bowel diseases - a diagnostic study. *Int J Colorectal Dis*, Oct 1. doi: 10.1007/s00384-018-3170-z. [Epub ahead of print]
106. Kredel LI, Schneidereit O, Hoffmann JC, **Siegmund B**, Preiß JC. Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice-results of a non-representative survey. *Int J Colorectal Dis*, 2018 Dec 7. doi: 10.1007/s00384-018-3215-3. [Epub ahead of print]

107. Böttcher C, Schlickeiser S, Sneeboer MAM, Kunkel D, Knop A, Paza E, Fidzinski P, Kraus L, Snijders GJL, Kahn RS, Schulz AR, Mei HE, NBB-Psy, Hol EM, **Siegmund B**, Glauben R, Spruth EJ, de Witte LD, Priller J. Human microglia regional heterogeneity and phenotypes determined by multiplexed single-cell mass cytometry. *Nature Neurosciences*, 2019, 22(1):78-90.

108. Bacher C, Hohnstein T, Beerbaum E, Röcker M, Blango MG, Kaufmann S, Röhmel J, Eschenhagen P, Seidel K, Rickerts V, Lozza L, Stervbo U, Nienen M, Babel N, Milleck J, Assenmacher M, Cornely OA, Ziegler M, Wisplinghoff H, Heine G, Worm M, **Siegmund B**, Maul J, Creutz P, Tabeling C, Ruwwe-Glösenkamp C, Sander LE, Knosalla C, Brunke S, Hube B, Kniemeyer O, Brakhage AA, Schwarz C, Scheffold A. Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans. *Cell*, 2019, 176(6):1340-1355.

109. Neeb L, Bayer A, Bayer KE; Farmer A, Fiebach JB, **Siegmund B**, Volz MS. Transcranial direct current stimulation in inflammatory bowel disease patients modifies resting-state functional connectivity: A RCT. *Brain Stimul* 2019 Mar 5. pii: S1935-861X(19)30080-4. doi: 10.1016/j.brs.2019.03.001. [Epub ahead of print]

110. Dignass AU, **Siegmund B**, Goertz R, Schneidewind G, Fanter L. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis. *Scand J Gastroenterol* 2019, 8:1-10.

111. Friedrich M, Gerbeth L, Gerling M, Rosenthal R, Steiger K, Weidinger C, Keye J, Wu H, Schmidt F, Weichert W, **Siegmund B**, Glauben R. HDAC inhibitors promote intestinal epithelial regeneration via autocrine TGFβ1 signalling in inflammation. *Mucosal Immunol* 2019, 12(3):656-667.

112. Petruo VA, Krauss E, Kleist A, Hardt J, Hake K, Peirano J, Krause T, Ehehalt R, von Arnauld de la Perrière P, Büning J, Treml O, Krauss N, Albrecht H, Felten G, Hermannspahn U, Burkhardt U, Eisold M, Teich N, **Siegmund B**, Maaser C, Bokemeyer B, Baumgart DC, Neurath MF, Mudter J, German IBD Study Group (GISG) KND. Perceived distress, personality characteristics, coping strategies and psychosocial impairments in a national German multicenter cohort of patients with Crohn's disease and ulcerative colitis. *Z Gastroenterol* 2019, 57(4):473-83.

113. Murray KA, Hoad CL, Garratt J, Kaviani M, Marciani L, Smith JK, **Siegmund B**, Gowland PA, Humes DJ, Spiller RC. A pilot study of visceral fat and its association with adipokines, stool calprotectin and symptoms in patients with diverticulosis. *PLoS One* 2019, 14(5):e0216528.

114. Visekruna A, Hartmann S, Sillke YR, Glauben R, Fischer F, Raifer H, Mollenkopf H, Bertrams W, Schmeck B, Klein M, Pagenstecher A, Lohoff M, Jacob R, Pabst O, Bland PW, Luu M, Romero R, **Siegmund B**, Rajalingam K, Steinhoff U. Intestinal development and homeostasis require activation and apoptosis of diet-reactive T cells. *J Clin Invest* 2019, 130:1972-83.

115. Hamesh K, Mandorfer M, Pereira, Moeller LS, Pons M, Dolman GE, Reichert MC, Heimes CV, Woditsch V, Voss J, Lindhauer C, Fromme M, Spivak I, Guldiken N, Zhou B, Arslanow A, Schaefer B, Zoller H, Aigner E, Reiberger T, Wetzel M, **Siegmund B**, Simões C, Gaspar R, Maia L, Costa D, Bento-Miranda M, van Helden J, Yagmur E, Bzdok D, Stolk J, Gleiber W, Knipel V, Windisch W, Mahadeva R, Bals R, Koczulla R, Barrecheguren M, Miravitlles M, Janciauskiene S, Stickel F, Lammert F, Liberal R, Genesca J, Griffith WJ, Trauner M, Krag A, Trautwein C, Strnad P; European Alpha1-Liver Study Group. Liver fibrosis and metabolic alterations in adults with alpha1 antitrypsin deficiency caused by Pi*ZZ mutation. *Gastroenterology* 2019 May 20. pii: S0016-5085(19)40894-9. doi: 10.1053/j.gastro.2019.05.013. [Epub ahead of print]

116. Schmidt F, Dahlke K, Batra A, Keye J, Wu H, Friedrich M, Glauben R, Ring C, Loh G, Schaubeck M, Hackl H, Trajanoski Z, Schumann M, Kühl AA, Blaut M, **Siegmund B**. Microbial colonization in adulthood shapes the intestinal macrophage compartment. *J Crohns Colitis* 2019 Apr 1. pii: jjz036. doi: 10.1093/ecco-jcc/jjz036. [Epub ahead of print]

2.3 Reviews, Editorials, Case Reports, Letters

2.3.1 Reviews

1. **Siegmund B.** Interleukin-1beta converting enzyme (caspase 1) in intestinal inflammation. *Biochem Pharmacol* 2002, 64:1-8.

2. **Siegmund B**, Zeitz M. Pralnacasan (vertex pharmaceuticals). *IDrugs* 2003, 6:154-8.
3. **Siegmund B**, Zeitz M. Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis. *Rocz Akad Med Bialymst* 2004, 49:22-30.
4. **Siegmund B**, Zeitz M. Standards of medical treatment and nutrition in Crohn's disease. *Langenbecks Arch Surg* 2005, 390:502-9.
5. Batra A, Zeitz M, **Siegmund B.** [The role of leptin in the immune system – a linking of endocrinology and immunology]. *Dtsch Med Wochenschr* 2005, 130:226-9.
6. **Siegmund B**, Zeitz M. [Ulcerative colitis? Guidelines 2004]. *Praxis (Bern1994)* 2005, 94:1599-604.
7. **Siegmund B**, Zeitz M. [Immunobiology of chronic inflammatory bowel diseases]. *Dtsch Med Wochenschr* 2006, 131:2657-60.
8. Hoffmann JC, Preiss JC, Autschbach F, Buhr HJ, Häuser W, Herrlinger K, Höhne W, Koletzko S, Krieglstein CF, Kruis W, Matthes H, Moser G, Reinshagen M, Rogler G, Schreiber S, Schreyer AG, Sido B, **Siegmund B,** Stallmach A, Bokemeyer B, Stange EF, Zeitz M. [Clinical practice guideline on diagnosis and treatment of Crohn's disease]. *Z Gastroenterol* 2008, 46:1094-146.
9. Hoffmann JC, Autschbach F, Bokemeyer B, Buhr HJ, Herrlinger K, Höhne W, Krieglstein CF, Kruis W, Moser G, Preiss JC, Reinshagen M, Rogler G, Schreiber S, Schreyer AG, **Siegmund B**, Stallmach A, Stange EF, Zeitz M. [Short version of the updated German S3 (level 3) guideline on diagnosis and treatment of Crohn's disease]. *Dtsch Med Wochenschr* 2008, 133:1924-9.
10. Preiss JC, Bokemeyer B, **Siegmund B**, Stange EF, Zeitz M, Hoffmann JC, German Gastroenterologic Society the Competence Network, I. B. D. [Clinical practice guideline on diagnosis and treatment of Crohn's disease – summary fort the general practitioner]. *Med Klin (Munich)* 2009, 104:237-43.
11. **Siegmund B**, Zeitz M. [Inflammatory bowel disease and pregnancy]. *Z Gastroenterol* 2009, 47:1069-74.
12. Batra A, Zeitz M, **Siegmund B**. Adipokine signaling in inflammatory bowel disease. *Inflamm Bowel Dis* 2009, 15:1897-1905.
13. **Siegmund B**, Zeitz M. Clinical aspects of inflammatory bowel disease. *Eur J Immunol* 2009, 39:2026-30.
14. Glauben R, Sonnenberg E, Zeitz M, **Siegmund B.** HDAC inhibitors in models of inflammation-related tumorigenesis. *Cancer Lett* 2009, 280:154-9.
15. **Siegmund B.** Targeted therapies in inflammatory bowel disease. *Dig Dis* 2009, 27:465-9.
16. **Siegmund B**, Preiss JC, Zeitz M. [What has been confirmed in the treatment of inflammatory bowel disease?]. *Internist* 2010, 51:1492-8.
17. Batra A, Stroh T, **Siegmund B**. Extraluminal factors contributing to inflammatory bowel disease. *World J Gastroenterol* 2011, 17:572-7.
18. Glauben R, **Siegmund B**. Inhibition of histone deacetylases in inflammatory bowel diseases. *Mol Med* 2011, 17:426-33.
19. Lissner D, **Siegmund B**. The multifaceted role of the inflammasome in inflammatory bowel diseases. *ScientificWorldJournal* 2011, 11:1536-47.
20. **Siegmund B**, Zeitz M. Innate and adaptive immunity in inflammatory bowel disease. *World J Gastroenterol* 2011, 17:3178-83.
21. Batra A, **Siegmund B**. The role of visceral fat. *Dig Dis* 2012, 30:70-4.
22. **Siegmund B**. [Chronic inflammatory bowel diseases: Clinical aspects and new therapy approaches]. *Pathologe* 2012, 33 Suppl 2:211-4.
23. Lissner D, **Siegmund B**. Ulcerative colitis: current and future treatment strategies. *Dig Dis* 2013, 31:91-4
24. Preiss, JC, Bokemeyer B, Buhr HJ, Dignass A, Häuser W, Hartmann F, Herrlinger KR, Kaltz B, Kienle P, Kruis W, Kucharzik T, Langhorst J, Schreiber S, **Siegmund B**, Stallmach A, Stange EF, Stein J, Hoffmann JC; German Society of Gastroenterology. [Updated German clinical practice guideline on "Diagnosis and treatment of Crohn's disease" 2014]. *Z Gastroenterol* 2014, 52:1431-84.

25. Seifarth C, Gröne J, Slavova N, **Siegmund B**, Buhr HJ, Ritz JP. [Proctocolectomy in ulcerative colitis: is a multistep procedure in cases of immunosuppression advisable?]. *Chirurg* 2014, 84:802-8.

26. Kruis T, Batra A, **Siegmund B**. Bacterial translocation – impact on the adipocyte compartment. *Front Immunol* 2014, 4:510.

27. **Siegmund B**. [Etiopathogenesis of chronic inflammatory bowel disease. Role of the immune system]. *Internist* 2014, 55:883-8.

28. Haag, LM, **Siegmund B**. Exploring & exploiting our 'other self' – does the microbiota hold the key to the future therapy in Crohn's? *Best Pract Res Clin Gastroenterol* 2014, 28:399-409.

29. Mössner J., **Siegmund B**. [Chronic inflammatory bowel diseases]. *Internist* 2014, 55:881-2.

30. Maul J, **Siegmund B**. [Chronic inflammatory bowel diseases: state of the art]. *Dtsch Med Wochenschr* 2014, 139:1771-5.

31. Schmidt C, Herrlinger K, **Siegmund B**, Bokemeyer B, Schreiber S, Stallmach A; Kompetenznetz Darmerkrankungen. [Azathioprine in Crohn's disease therapy – guidance against the background of recent studies]. *Z Gastroenterol* 2014, 52:1423-30.

32. Kredel LI, Batra A, **Siegmund B**. Role of fat and adipokines in intestinal inflammation. *Curr Opin Gastroenterol* 2014, 30:559-65.

33. Kredel LI, **Siegmund B**. Adipose-tissue and intestinal inflammation – visceral obesity and creeping fat. *Front Immunol* 2014, 5:462.

34. **Siegmund B**. Management of mild-to moderate ulcerative colitis. *Dig Dis* 2015, 33 Suppl 1:90-4.

35. Haag LM, **Siegmund B**. Intestinal microbiota and the innate immune system – a crosstalk in Crohn's disease pathogenesis. *Front Immunol* 2015, 6:489.

36. **Siegmund B**. Medical therapy of fibrostenotic Crohn's disease. *Viszeralmedizin* 2015, 31:259-64.

37. Lamprecht G, Atreya R, Kreis ME, **Siegmund B**, Stallmach A. Inflammatory bowel diseases: current medical and surgical therapy. *Viszeralmedizin* 2015, 31:287-9.

38. Kühl AA, Erben U, Kredel LI, **Siegmund B**. Diversity of intestinal macrophages in inflammatory bowel diseases. *Front Immunol* 2015, 6:613.

39. Schreiber S, Dignass A, Hartmann H, Kruis W, Rogler G, **Siegmund B**, Stallmach A, Witte C, Bokemeyer B. [Current position on Veodlizumab for ulcerative colitis and Crohn's disease]. *Z Gastroenterol* 2015, 53:591-602.

40. Schreiber S, Hartmann H, Kruis W, Kucharzik T, Mudter J, **Siegmund B**, Stallmach A, Witte C, Fitzke K, Bokemeyer B. [Inflammatory Bowel Disease Competence Network]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2016, 59:465-74.

41. Mattner J, Schmidt F, **Siegmund B**. Faecal microbiota transplantation – a clinical view. *Int J Med Microbiol* 2016, doi: 10.2016/j.imm.2016.02.003.

42. Volz MS, **Siegmund B**, Häuser W. [Efficacy, tolerability, and safety of cannabinoids in gastroenterology: a systematic review]. *Schmerz* 2016, 30:37-46.

43. **Siegmund B**, Feakins RM, Bamias G, Coelho LJ, Teixeira FV, Rogler G, Scharl M. Results of the 5th scientific workshop of the ECCO (II): Pathophysiology of perianal fistulising disease. *J Crohns Colitis* 2016, 10:377-86.

44. Lissner D, **Siegmund B**. Are immunosuppressants becoming obsolete? *Dig Dis* 2016 34 Suppl. 1:56-60.

45. **Siegmund B**, Atreya R, Bokemeyer B, Kruis W, Mudther J, Sander C, Schreiber S, Reindl W, Zeissig S, Kucharzik T. [Biosimilars in inflammatory bowel disease]. *Z Gastroenterol* 2016, 54:1217-22.

46. Paeschke A, Erben U, Kredel LI, Kühl AA, **Siegmund B**. Role of visceral fat in colonic inflammation: from Crohn's disease to diverticulitis. *Curr Opin Gastroenterol* 2017, 33(1):53-58.

47. Sonnenberg E, **Siegmund B**. Ulcerative Colitis. *Digestion* 2016, 94(4):181-85.

48. Lynen-Jansen P, **Siegmund B**, Nothacker M, Zeuzem S. Das Leitlinienprogramm der DGVS 2017. *Z Gastroenterol* 2017, 55:39-49**.**

49. **Siegmund B**. Cytomegalovirus infection associated with inflammatory bowel diseases. *Lancet Gastro Hepatol* 2017, 2(5):369-76.

50. Martini E, Krug SM, **Siegmund B**, Neurath MF, Becker C. Mend your fences: The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. *Cell Mol Gastroenterol Hepatol* 2017, 4(1):33-46.

51. Schumann M, **Siegmund B**, Schulzke JD, Fromm M. Celiac disease: role of the epithelial barrier. *Cell Mol Gastroenterol Hepatol* 2017, 3(2):150-62.

52. Zundler S, Becker E, Weidinger C, **Siegmund B**. Anti-adhesion therapies in inflammatory bowel disease-molecular and clinical aspects. *Front Immunol* 2017, 8:891. doi: 10.3389/fimmu.2017.00891. eCollection 2017.

53. Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, Hotchkiss R, Joosten LAB, Kastner DL, Korte M, Latz E, Libby P, Mandrup-Poulsen T, Mantovani A, Mills KHG, Nowak KL, O'Neill LA, Pickkers P, van der Poll T, Ridker PM, Schalkwijk J, Schwartz DA, **Siegmund B**, Steer CJ, Tilg H, van der Meer JWM, van de Veerdonk FL, Dinarello CA. A guiding map for inflammation. *Nat Immunol* 2017, 18(8):826-831.

54. Atreya R, **Siegmund B**. IBD in 2017: Development of therapy for and prediction of IBD - getting personal. *Nat Rev Gastroenterol Hepatol* 2018, 15(2):72-74.

55. Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (federführend); Deutsche Gesellschaft für Innere Medizin (DGIM); Deutsche M. Crohn/Colitis ulcerosa Vereinigung (DCCV); Deutsche Leberhilfe e.V; Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM); Deutsche Gesellschaft für Endoskopie und Bildgebende Verfahren (DGE-BV); Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ); Gesellschaft für Pädiatrische Gastroenterologie (GPGE); Deutsche Gesellschaft für Rheumatologie (DGRh); Deutsche Röntgengesellschaft (DRG); Deutsche Transplantationsgesellschaft (DTG); Deutsche Gesellschaft für Pathologie (DGP) und Bundesverband Deutscher Pathologen (BDP); Österreichische Gesellschaft für Gastroenterologie (ÖGG); Schweizer Gastroenterologische Gesellschaft (SGG). [Practice guideline autoimmune liver disease - AWMF-Reg. No. 021-27]. *Z Gastroenterol* 2017, 55(11):1135-1226.

56. Weidinger C, Hegazy AN, **Siegmund B**. The role of adipose tissue in IBD. *Curr Opin Gastroenterol* 2018, 34(4):183-86.

57. Müther S, Oldhafer M, **Siegmund B**. [Transition medicine-structural solutions]. *Internist* (Berl). 2018 Sep 21. doi: 10.1007/s00108-018-0499-x

58. **Siegmund B**, Högenauer C, Novacek G, Petrisch W, Reinisch W, Schoepfer A, Schreiber S, Vavricka S, Bokemeyer B; für die IBD-Dach-Gruppe. [Ustekinumab - Current position]. *Z Gastroenterol* 2018, 56(9):1077-1086.

59. Lissner D, Sonnenberg E, **Siegmund B**. [Inflammatory bowel disease: cardinal signs and their diagnosis]. *Dtsch Med Wochenschr* 2018, 113(13):937-944.

60. Kucharzik T, Dignass AU, ATreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, **Siegmund B**. [Updated S3-Guideline Colitis ulcerosa. German Society for Digestive and Metabolic Diseases (DGVS) - AWMF Registry 021/009]. *Z Gastroenterol* 2018, 56(9):1087-1169.

61. Weidinger C, Ziegler JF, Letizia M, Schmidt F, **Siegmund B**. Adipokines and their role in intestinal inflammation. *Front Immunol* 2018, 9:1974.

62. Müther S, Oldhafer M, **Siegmund B**. [Transition medicine-structural solutions]. *Internist (Berl)*, 2018, 59(11):1128-1132.

2.3.2 Editorials

1. **Siegmund B**, Zeitz M. Transglutaminases: new target molecules for inflammatory bowel disease? *Gut* 2005, 54:443-4.

2. **Siegmund B**, Nau C, Schölmerich J, Thimme R. [Career path in German university medicine]. *Dtsch Med Wochenschr* 2009, 134:1587-90.

3. **Siegmund B**. Interleukin-18 in intestinal inflammation: friend and foe? *Immunity* 2010, 32:300-2.

4. Stallmach A, Bauer M, Otto W, **Siegmund B.** Hochschulmedizin: Strategien zur Sicherung des wissenschaftlichen Nachwuchses. *Deutsches Ärzteblatt* 2011, 108(7):A381-4.
5. **Siegmund B**. Mesenteric fat in Crohn's disease: the hot spot of inflammation? *Gut* 2012, 61:3-5.
6. Schulzke JD, **Siegmund B**, Günzel D. New insights into intestinal secretion. *Gut* 2014, 63:1371-2.
7. Syrbe U, **Siegmund B**. Bone marrow Th17 TNFalpha cells induce osteoclast differentiation and link bone destruction to IBD. *Gut* 2015, 64:1011-12.
8. Schumann M, Daum S, Preiss JC, Baas S, Stallmach A, **Siegmund B**, Weber M. [Rare diseases on the trail – the registry for refractory sprue]. *Z Gastroenterol* 2015, 53:136.
9. **Siegmund B**. Kurzkommentar "Ustekinumab as Induction and Maintenance Therapy for Crohn's disease". *Der Internist* 2017, 58(4):424-426.
10. **Siegmund B**. Is intensity the solution for FMT in ulcerative colitis? *The Lancet* 2017, 389(10075):1170-72.
11. Leppkes M, **Siegmund B**, Becker C. Immune-Epithelial Crosstalk in Inflammatory Bowel Diseases and Mucosal Wound Healing. *Front Immunol* 2018, 9:1171.
12. **Siegmund B**, Lehnert H, Manns M. [Transition medicine]. *Internist (Berl)*, 2018, 59(11):1125-1127.

2.3.3 Case Reports

1. **Siegmund B**, Folwaczny C, Bader L, Otto B, Hoelscher M, Leinsinger G, Herzer P, Loeschke K. Multiple Muskelabszesse bei tibetanischer Patientin. *Der Internist* 2000, 41, 903-7.
2. **Siegmund B**, Moos V, Loddenkemper C, Wahnschaffe U, Engelmann E, Zeitz M, Schneider T. Esophageal giant ulcer in primary human immunodeficiency virsu-infection is associated with an infiltration of activated T cells. *Scand J Gastroenterol* 2007, 42:890-5.
3. Schumann M, Preiss JC, Loddenkemper C, Günther U, Somasundaram R, **Siegmund B**, Zeitz M. [Nodular regenerative hyperplasia as a side effect of azathioprine in a patient with Crohn's disease]. *Dtsch Med Wochenschr* 2008, 133:1897-900.
4. Weinberg G, **Siegmund B**, Grünbaum M, Loddenkemper C, Schneider T. Cytomegalovirus-esophagitis as initial presentation of HIV infection mimicking adenocarcinoma. *Endoscopy* 2010, 42 Suppl. 2:E22-3.
5. Holmer C, Zurbuchen U, **Siegmund B**, Reichelt U, Buhr HJ, Ritz JP. Clostridium difficile infection of the small bowel – two case reports with a literature survey. *Int J Colorectal Dis* 2011, 26:245-51.
6. Seifarth C, Ritz JP, Pohlen U, Kroesen AJ, **Siegmund B**, Frericks B, Buhr HJ. Therapy of complicated Crohn's disease during pregnancy – an interdisciplinary challenge. *Int J Colorectal Dis* 2014, 29:645-51.
7. Volz MS, Nassir M, Treese C, von Winterfeld M, Plöckinger U, Epple HJ, **Siegmund B**. Inflammatory bowel disease (IBD)-like disease in a case of a 33-year old man with glykogenosis 1b. *BMC Gastroenterol* 2015, 15:45.
8. Kruis T, Jöhrens K, Moos V, Puls I, **Siegmund B**, Daum S, Schumann M. A case series in patients with enteropathy and granulomatous diseases. *BMC Gastroenterol* 2015; 53:62.
9. Haag LM, Hofmann J, Kredel LI, Holzem C, Kühl AA, Taube ET, Schubert S, **Siegmund B**, Epple HJ. Herpes simplex virus sepsis in a young woman with Crohn's disease. *J Crohns Colitis* 2015; 9:1169-73
10. Paeschke A, Bojarski C, Küpferling S, Hucklenbroich T, **Siegmund B**, Daum S. Unintentional long-term esophageal stenting due to a complete response in a patients with stage UICC IV adenocarcinoma of the gastroesophageal junction. *Case Rep Gastroenterol* 2016; 10:218-23.

2.3.4 Letters

1. Lissner D, Glauben R, Allers K, Sonnenberg E, Loddenkemper C, Schneider T, **Siegmund B**. Pulmonary manifestation of Crohn's disease developed under treatment with Vedolizumab. *Am J Gastroenterol* 2018; 113(1):146-148.

2.4 Book Chapters

1. **Siegmund B**. 4.5 Medikamentöse Therapie in Orientierung an der Klinik: Seltene CED. In: Hoffmann J. C., Kroesen A. J., Klump B. (Hrsg.): Chronisch entzündliche Darmerkrankungen. 1. Auflage Georg Thieme Verlag (2004) 184-189.
2. **Siegmund B**. 20. Why and how should we target tumour necrosis factor-α and interleukin-18? In: Duchmann R., Blumberg RS, Neurath MF, Schölmerich J, Strober W, Zeitz M. (Hrsg.): Falk Symposium 133 Mechanisms of intestinal inflammation – Implications for therapeutic intervention in IBD. Kluwer Academic Publishers (2004) 166-176.
3. **Siegmund B**, Zeitz M. Chronische Entzündliche Darmerkrankungen. Deutsche Ausgabe (Autoren Friedman S, Blumberg RS). In: Dietel M, Suttorp N, Zeitz M. (Hrsg.): Harrisons Innere Medizin. Teil 2. 16. Auflage (2005) 1911-24.
4. Batra A, **Siegmund B.** Leptin and Gastrointestinal Inflammation. In: Fantuzzi G, Mazzone T. (Hrsg.): Adipose Tissue and Adipokines in Health and Disease. Humana Press (2007) 101-10.
5. Glauben R, **Siegmund B.** Molecular basis of histone deacetylase inhibitors as new drugs for the treatment of inflammatory disease and cancer. In: Kozlov S. (Hrsg.): Inflammation and Cancer Methods and Protocols. Volume 2: Molecular Analysis and Pathways. Humana Press (2009) Part II Chapter 21 365-76.
6. **Siegmund B**. 4.7 Medikamentöse Therapie in Orientierung an der Klinik: Seltene CED. In: Hoffmann JC, Kroesen AJ, Klump B. (Hrsg.): Chronisch entzündliche Darmerkrankungen. 2. Auflage Georg Thieme Verlag (2009) 246-51.
7. Preiß J, **Siegmund B**. 4.4 Biologika bei CED. In: Hoffmann JC, Kroesen AJ, Klump B. (Hrsg.): Chronisch entzündliche Darmerkrankungen. 2. Auflage Georg Thieme Verlag (2009) 212-6.
8. **Siegmund B**. Targeted Therapies in Inflammatory Bowel Disease. In: Buhr HJ, Karchenko NV, **Siegmund B**, Zacharash MP, Zeitz M. (Hrsg.): Inflammation in the Intestinal Tract: Pathogenesis and Treatment. Falk Symposium 169. Karger AG Basel (2009) 465-9.
9. **Siegmund B**, Zeitz M. Chronische Entzündliche Darmerkrankungen. Deutsche Ausgabe (Autoren Friedman S, Blumberg RS). In: Dietel M, Suttorp N, Zeitz M. (Hrsg.): Harrisons Innere Medizin. Teil 2. ABW Wissenschaftsverlag. 17. Auflage (2009) 2327-43.
10. Glauben R, Sonnenberg E, **Siegmund B**. Protective effects of epigenetic modifications in experimental inflammatory bowel disease. In: Zouali M (Hrsg.): The Epigenetics of Autoimmune Diseases. 1. Auflage Wiley-Blackwell (2009) 373-384.
11. **Siegmund B**. Malassimilationssyndrom. In: Brunkhorst R, Schölmerich J. (Hrsg.): Differenzialdiagnostik und Differenzialtherapie. Entscheidungen in der Inneren Medizin. 1. Auflage Urban & Fischer (2010) 376-377.
12. **Siegmund B**. Glutensensitive Enteropathie. In: Brunkhorst R, Schölmerich J. (Hrsg.): Differenzialdiagnostik und Differenzialtherapie. Entscheidungen in der Inneren Medizin. 1. Auflage Urban & Fischer (2010) 326-327.
13. Daum S, **Siegmund B**, Zeitz M. Immunerkrankungen des Intestinaltrakts inklusive intestinaler Lymphome. In: Messmann H. (Hrsg.): Klinische Gastroenterologie. 1. Auflage Thieme Verlag (2012) 347-54.
14. **Siegmund B**, Zeitz M. Kapitel 16 Chronisch entzündliche Darmerkrankungen. Deutsche Ausgabe (Autoren Friedman S, Blumberg RS). In: Zeitz M, Schmidt H H-J, Bojarski C (Hrsg.): Harrisons Gastroenterologie und Hepatologie. ABW Wissenschaftsverlag. 1. Auflage (2011) 197-225
15. **Siegmund B**, Zeitz M. Kapitel 295 Chronische Entzündliche Darmerkrankungen. German Edition (authors Friedman S, Blumberg RS). In: Dietel M, Suttorp N, Zeitz M. (Hrsg.): Harrisons Innere Medizin. ABW Wissenschaftsverlag Teil 2. 18. Auflage (2012) 2674-2694.
16. Rodeck B, **Siegmund B**, Radke M. Kapitel 11 Chronisch entzündliche Darmerkrankungen. In: Oldhafer M (Hrsg.): Transitionsmedizin. 1. Auflage Schattauer GmbH (2016) 104-18.
17. Schumann M, **Siegmund B**. Kapitel 7 Gluten-Enteropathie. In: Stange EF (Hrsg.): Entzündliche Darmerkrankungen. Klinik, Diagnostik und Therapie. 1. Auflage Schattauer GmbH (2016) 295-307.
18. Epple HJ, Tröger H, **Siegmund B**. Kapitel 22 Gastrointestinal infection and parasites. In: Handbook in Gastroenterology and Liver Disease. Minerva Medica (2016) 171-9.

19. Daum S, **Siegmund B**. F8 Dünndarmstörungen als Teilaspekt systemischer Erkrankungen. In: Sauerbruch T (Hrsg.): Therapie-Handbuch. 5. Auflage Urban & Fischer (2016) F8-1 – F8-4.2.
20. Schumann M, **Siegmund B**. Kapitel 7 Gluten-Enteropathie. In: Stange EF (Hrsg.): Entzündliche Darmerkrankungen. Klinik, Diagnostik und Therapie. 1. Auflage Schattauer GmbH (2016) 295-307.
21. Epple HJ, Tröger H, **Siegmund B**. Kapitel 22 Gastrointestinal infection and parasites. In: Handbook in Gastroenterology and Liver Disease. Minerva Medica (2016) 171-9.
22. **Siegmund B**. Malassimilationssyndrom. In: Brunkhorst R, Schölmerich J. (Hrsg.): Differenzialdiagnostik und Differenzialtherapie. Entscheidungen in der Inneren Medizin. 2. Auflage Elsevier (2018) 376-377.
23. Schumann M, **Siegmund B**. Glutensensitive Enteropathie. In: Brunkhorst R, Schölmerich J. (Hrsg.): Differenzialdiagnostik und Differenzialtherapie. Entscheidungen in der Inneren Medizin. 2. Auflage Elsevier (2018) 326-327.
24. **Siegmund B**. Kapitel 351 Chronisch Entzündliche Darmerkrankungen. German Edition (authors: Friedman S, Blumberg RS). In: Suttorp N, Möckel M, **Siegmund B**, Dietel M. (Hrsg.): Harrisons Innere Medizin. Thieme Verlag Teil 3. 19. Auflage (2016) 2390-2411.
25. **Siegmund B**, Minden K, Müther S. Kapitel 31 Transition. In: Stier B, Weissenrieder N, Schwab KO (Hrsg.): Jugendmedizin, 2. Auflage (2018) 379-383.
26. Epple HJ, **Siegmund B**. F43 Akute infektiöse Enteritiden bei Erwachsenen. In: Sauerbruch T (Hrsg.): Therapie-Handbuch Jahrbuch 2018. 1. Auflage (2018) 337-344.
27. Daum S, **Siegmund B**. F44 Dünndarmstörungen als Teilaspekt systemischer Erkrankungen. In: Sauerbruch T (Hrsg.): Therapie-Handbuch Jahrbuch 2018. 1. Auflage (2018) 345-347.
28. Schmidt F, **Siegmund B**. Kapitel 20 Fecal Transplantation. In: Haller D (Hrsg.): The Gut Microbiome in Health and Disease. 1. Auflage Springer (2018) 327-339.